Melbourne Haematology

Assoc Prof Philip Campbell consulting at: Geelong

Epworth Geelong
Sessional Consulting Suites
Level 1, 1 Epworth Place
Waurn Ponds VIC 3221
Tel: 03 5271 7800
Fax: 03 5271 7797

View Map of Room's Location

Private Hospital Accreditations
St John of God Hospital
Geelong Private Hospital

---

MB ChB FRCP FRACP FRCPath FRCPA

• Clinical Associate Professor
  Deakin University Medical School
• Andrew Love Cancer Centre
  Geelong Hospital, Barwon Health
• Clinical Haematologist

Philip Campbell is a general haematologist with broad training and experience in malignant and non-malignant haematology.

His main clinical interests are malignant haematology (leukaemia, lymphoma, myeloma and autologous stem cell transplantation) and clinical research, particularly multi centre collaborative research in malignant haematology.

Assoc Prof Philip Campbell's areas of interest also include haematological oncology, clinical research and obstetric haematology.

Society Memberships

• Haematology Society of Australia and New Zealand
• British Society of Haematology
• Australasian Leukaemia and Lymphoma Group
• Australasian Society of Thrombosis and Haemostasis
• Australasian Society of Blood Transfusion
• Australasian Society of Bone Marrow Transplantation
• American Society of Haematology.

Present Appointments:

October 2001 - Senior Staff Specialist, Clinical Haematology, The Andrew Love
Cancer Centre, Geelong Hospital, Geelong, Victoria, Australia

Clinical Tutor, University of Melbourne, Geelong and St. Vincent’s
Hospital Clinical School 2002-2009

Clinical Associate Professor, School of Medicine, Faculty of Health,
Medicine, Nursing and Behavioural Sciences, Deakin University

Publications

1. Campbell PJ, Ryan KE, Olatunji P, Davies SC. Splenic regrowth in sickle cell anaemia following hypertransfusion. British Journal of Haematology 1997; 96: 77-79
2. Campbell PJ, Tirvengadum MA, Pickering W, Cohen H, Ryan KE.HEPTEST: A suitable method for monitoring heparin prophylaxis during pregnancy. Clinical and Laboratory Haematology 1999; 21, 193-199
3. Campbell P, Iland H, Gibson J, Joshua D. Syngeneic stem cell transplantation for HIV-related lymphoma. British Journal of Haematology 1999; 105: 795-798
4. Tam C, Seymour J, Brown M, Campbell P, Scarlett J, Underhill C, Ritchie D, Bond R, Grigg A. An analysis of the early and late infectious consequences of the addition of Rituximab to Fludarabine and Cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica 2005; 90:700-702
5. Field K, McFarlane C, Cheng AC, Hughes AJ, Jacobs E, Styles K, Low J, Stow P, Campbell P, Athan E. Incidence of bloodstream infection and a mechanical valve needle-free system in an Australian Haematology-Oncology Unit. Infection Control and Hospital Epidemiology 2007 May; 28(5): 610-613
6. Saravanan L, Brennan S, George P, Lowen R, Kirkland M, Campbell P. Novel Fibrinogen Aa chain mutation associated with afibrinogenemia. Pathology. October 2007; 39(5): 519-520
7. Azad A, Campbell P. High rates of infection associated with the use of maintenance Rituximab monotherapy in non-Hodgkin lymphoma. Internal Medicine Journal. 2009 November; 39:778-779
8. Kenealy M, Seymour JF, Cowan L, Milner A, Giri P, Ho SJ, Benson W, Nicol A, Campbell P, Prosser I, Underhill C, Cunningham I, Mills A, Szer J, Presgrave P, Filshie R. The tolerability of combination therapy with Thalidomide and 5-Azacitidine in patients with advanced myelodysplastic syndromes (MDS). Blood 2009. 114(22); 1749A
9. Fung CY, Grigoriadis G, Hocking J, Campbell P, Schwarer AP, Walker PA, Avery S, Patil SS, Salem HH, Spencer A, Wei A. Initial remission duration is the most important predictor of outcome following FLAG-Amsacrine salvage of AML in first relapse. Blood 2011. 118; 3631